Compare DRTS & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRTS | WVE |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | Israel | Singapore |
| Employees | 121 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 978.2M | 1.1B |
| IPO Year | N/A | 2015 |
| Metric | DRTS | WVE |
|---|---|---|
| Price | $13.48 | $5.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | $8.67 | ★ $29.81 |
| AVG Volume (30 Days) | 784.7K | ★ 3.1M |
| Earning Date | 05-18-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,704,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $699.98 | $85.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $2.87 | $5.02 |
| 52 Week High | $14.11 | $21.73 |
| Indicator | DRTS | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 65.06 | 44.59 |
| Support Level | $6.59 | $5.48 |
| Resistance Level | $14.11 | $6.48 |
| Average True Range (ATR) | 0.95 | 0.32 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 82.93 | 34.54 |
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.